We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Merck and DNAtrix Announce Collaboration

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Merck and DNAtrix Announce Collaboration"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Merck and DNAtrix have announced that they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.

DNX-2401 is a conditionally replicative oncolytic adenovirus designed to specifically target cells defective in the Retinoblastoma (Rb) pathway, which is present in many cancers. Several DNX-2401 clinical studies have demonstrated a favorable safety profile and strong tumor-killing potential in patients with recurrent glioblastoma.

KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. KEYTRUDA is currently approved in the United States for certain types of advanced metastatic melanoma.

“We are excited to enter into this important collaboration with Merck as we investigate the potential anti-tumor effect that combining our two immunotherapies – DNX-2401 and KEYTRUDA – may offer patients with this aggressive disease,” said Frank Tufaro, Ph.D., chief executive officer of DNAtrix.

“The collaboration with DNAtrix further strengthens our efforts to progress the field of immuno-oncology and identify potential combinations that will significantly advance the care of people with cancers for which there have been few advancements,” said Dr. Eric Rubin, vice president and therapeutic area head, oncology early-stage development, Merck Research Laboratories. “We look forward to studying the potential synergistic effects that combining DNX-2401 and KEYTRUDA could have in the treatment of patients with recurrent glioblastoma.”